Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Total 13F shares
-
19,183,314
-
Share change
-
-3,020
-
Total reported value
-
$33,762,501
-
Put/Call ratio
-
361%
-
Price per share
-
$1.76
-
Number of holders
-
46
-
Value change
-
+$90,871
-
Number of buys
-
15
-
Number of sells
-
18
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q4 2023
As of 31 Dec 2023,
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,183,314 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, SAMLYN CAPITAL, LLC, BVF INC/IL, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., TOWERVIEW LLC, GEODE CAPITAL MANAGEMENT, LLC, and MORGAN STANLEY.
This page lists
46
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.